Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Women’s Infertility Therapeutics - Pipeline Assessment and Market Forecasts to 2018The Women’s Infertility Therapeutics Market is Forecast to Show Slow Growth until 2018
By: Rajesh Gunnam 2010. The market is estimated to grow at a Compound Annual Growth Rate (CAGR) of 3.3%, to reach $2,317m by 2018. The slow market growth is attributed to the weak pipeline and patent expiry of some of the products such as Luveris, Follistim AQ and Ganirelix Acetate Injection. These products are approaching patent expiry in the US in 2015. Therefore, these products would face competition from the generic versions. A key driver for the women’s infertility therapeutics market is the increasing patient population. Over the past few years a shift in the diseased population has been registered. The key factors responsible for this shift include changing lifestyle and increase in the risk factors leading to infertility in women; these risk factors are late marriage, smoking, obesity and alcohol use. The current women’s infertility therapeutics market has low unmet need, which is largely due to good efficacy and safety of the currently prescribed drugs and high levels of physician and patient satisfaction. During 2000-2005, the approval of recombinant forms of gonadotropins such as Luveris, Gonal-f, Follistim AQ, and Bravelle, which offer better safety and efficacy, has resulted in relatively high growth of the market through the historic period (2005-2010). The women’s infertility pipeline consists of 22 drugs in various phases of development. Of these drugs, only one drug (PGL 1001), currently in preclinical development, is first-in-class. This signifies that the pipeline is weak. The Phase III clinical pipeline includes me-too drugs such as DA-3801 (ovulation induction), Elonva (controlled ovarian stimulation) For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ GlobalData’s analysis indicates that the women’s infertility therapeutics market is highly competitive, and has some highly successful branded and generic drugs. The market consists of treatment options such as human Chorionic Gonadotropin (hCG), Gonadotropin- Pharmaceuticals have a strong presence in the current market. GlobalData, the industry analysis specialist, has released its new report, “Women’s Infertility Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global women’s infertility market. The report identifies the key trends shaping and driving the global women’s infertility market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global women’s infertility sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number